On 4 August 2015, the EU Commission approved the acquisition by Pfizer of Hospira, a US-based competitor in, amongst other areas, biosimilar drugs and sterile injectable drugs. In order to obtain approval, Pfizer agreed to a number of divestments designed to eliminate actual or potential overlaps in the parties’ product
The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Pfizer / Hospira)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.